Deciphera Pharmaceuticals Inc.

12.46-0.2200-1.74%Vol 410.59K1Y Perf -33.40%
Oct 4th, 2023 16:00 DELAYED
BID12.15 ASK13.05
Open12.65 Previous Close12.68
Pre-Market- After-Market12.46
 - -  - -%
Target Price
20.60 
Analyst Rating
Strong Buy 1.25
Potential %
65.33 
Finscreener Ranking
★★★★ —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★     51.74
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
1.25 
Earnings Rating
Strong Buy
Market Cap982.11M 
Earnings Date
2nd Nov 2023
Alpha0.00 Standard Deviation0.20
Beta0.70 

Today's Price Range

12.4412.70

52W Range

12.3322.76

5 Year PE Ratio Range

-10.40-12.10

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.20%
1 Month
-10.55%
3 Months
-10.30%
6 Months
-15.98%
1 Year
-33.40%
3 Years
-77.57%
5 Years
-60.01%
10 Years
-

TickerPriceChg.Chg.%
DCPH12.46-0.2200-1.74
AAPL173.661.26000.73
GOOG136.272.97002.23
MSFT318.965.56501.78
XOM111.50-4.3300-3.74
WFC38.970.30000.78
JNJ155.520.18000.12
FB196.640.99000.51
GE108.851.09001.01
JPM143.350.64000.45
Financial StrengthValueIndustryS&P 500US Markets
5.10
5.60
0.07
0.08
1.54K
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
95.00
-183.60
-181.10
-
-
RevenueValueIndustryS&P 500US Markets
97.69M
1.45
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.62-0.578.06
Q01 2023-0.60-0.600.00
Q04 2022-0.57-0.60-5.26
Q03 2022-0.57-0.553.51
Q02 2022-0.65-0.607.69
Q01 2022-0.84-0.804.76
Q04 2021-1.49-1.51-1.34
Q03 2021-1.29-1.37-6.20
Earnings Per EndEstimateRevision %Trend
9/2023 QR-0.601.64Positive
12/2023 QR-0.586.45Positive
12/2023 FY-2.364.45Positive
12/2024 FY-2.17-1.88Negative
Next Report Date2nd Nov 2023
Estimated EPS Next Report-0.60
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume410.59K
Shares Outstanding78.82K
Shares Float47.51M
Trades Count5.48K
Dollar Volume5.15M
Avg. Volume390.52K
Avg. Weekly Volume366.49K
Avg. Monthly Volume418.81K
Avg. Quarterly Volume386.26K

Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) stock closed at 12.46 per share at the end of the most recent trading day (a -1.74% change compared to the prior day closing price) with a volume of 410.59K shares and market capitalization of 982.11M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 350 people. Deciphera Pharmaceuticals Inc. CEO is Steven L. Hoerter.

The one-year performance of Deciphera Pharmaceuticals Inc. stock is -33.4%, while year-to-date (YTD) performance is -23.98%. DCPH stock has a five-year performance of -60.01%. Its 52-week range is between 12.33 and 22.76, which gives DCPH stock a 52-week price range ratio of 1.25%

Deciphera Pharmaceuticals Inc. currently has a PE ratio of -6.20, a price-to-book (PB) ratio of 3.91, a price-to-sale (PS) ratio of 14.17, a price to cashflow ratio of -, a PEG ratio of -0.09, a ROA of -50.01%, a ROC of -55.03% and a ROE of -63.61%. The company’s profit margin is -%, its EBITDA margin is -181.10%, and its revenue ttm is $97.69 Million , which makes it $1.45 revenue per share.

Of the last four earnings reports from Deciphera Pharmaceuticals Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.60 for the next earnings report. Deciphera Pharmaceuticals Inc.’s next earnings report date is 02nd Nov 2023.

The consensus rating of Wall Street analysts for Deciphera Pharmaceuticals Inc. is Strong Buy (1.25), with a target price of $20.6, which is +65.33% compared to the current price. The earnings rating for Deciphera Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Deciphera Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Deciphera Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.41, ATR14 : 0.48, CCI20 : -96.11, Chaikin Money Flow : -0.26, MACD : -0.40, Money Flow Index : 29.23, ROC : -8.72, RSI : 36.57, STOCH (14,3) : 7.18, STOCH RSI : 0.34, UO : 42.23, Williams %R : -92.82), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Deciphera Pharmaceuticals Inc. in the last 12-months were: Associates LLC. Brightstar (Buy at a value of $29 999 988), Associates LLC. Brightstar (Sold 0 shares of value $-24 277 ), Daniel C. Martin (Sold 4 000 shares of value $69 377 ), Daniel L. Flynn (Sold 3 773 shares of value $71 728 ), Daniel Lee Flynn (Sold 5 428 shares of value $95 559 ), Franklin Stuart Friedman (Buy at a value of $138 800), Jama Pitman (Sold 2 762 shares of value $51 550 ), Matthew L. Sherman (Sold 3 374 shares of value $65 704 ), Pitman Jama (Sold 4 000 shares of value $69 376 ), Sherman Matthew (Sold 5 029 shares of value $89 534 ), Steven L. Hoerter (Sold 67 590 shares of value $1 078 222 ), Thomas P. Kelly (Sold 3 773 shares of value $71 728 ), Thomas Patrick Kelly (Sold 5 428 shares of value $95 559 ), Walsh Dennis (Buy at a value of $152 460)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (87.50 %)
7 (87.50 %)
6 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (12.50 %)
1 (12.50 %)
2 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.25
Strong Buy
1.50

Deciphera Pharmaceuticals Inc.

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

CEO: Steven L. Hoerter

Telephone: +1 781 209-6400

Address: 200 Smith Street, Waltham 02451, MA, US

Number of employees: 350

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

53%47%

Bearish Bullish

55%45%

 

News

Stocktwits